dTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular Carcinoma
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorSun Yat-sen University
About this trial
This study intends to evaluate the efficacy and safety of drug-eluting transcatheter arterial embolization-hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin (dTACE-HAIC) plus Bevacizumab and Atezolizumab for patients with intermediate-advanced huge hepatocellular carcinoma.
Eligibility criteria
Qualifiers
Clinical diagnosis of HCC.
Age between 18 and 75 years;
The maximum tumor size ≥10 cm;
Intermediate-advanced huge HCC, advanced HCC with PVTT type I-III
Disqualifiers
Diffuse HCC;
Extrahepatic metastasis >5;
Obstructive PVTT involving mesenteric vena cava (PVTT IV).
Serious medical comorbidities.
Trial design
Treatments tested in this trial
- dTACE-HAIC
Treatment groups
27 Participants
are divided into 1 treatment groupLocations
1Chinese PLA General hospital100853, BeijingNone Selected, China
Sponsors and collaborators
Sun Yat-sen University
Lead sponsor
Source ClinicalTrials.gov